Rationale:
Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown.
Objective:
To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.

开始日期2024-05-01

申办/合作机构

University of Amsterdam

[+5]

NCT05333523 / Recruiting临床3期IIT

Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Patients With Squamous Cell Carcinoma of the Oropharynx, Larynx or Hypopharynx With a Clinically Negative Neck: (Chemo)Radiotherapy to the PRIMary Tumor Only. The PRIMO Study.

See detailed description.

开始日期2023-11-10

申办/合作机构

Radboud University Medical Center

[+7]

NCT06301945 / RecruitingN/AIIT

Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.
In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.
The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.
In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.
The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

开始日期2023-08-01

申办/合作机构

MAASTRO clinic

[+1]

100 项与 MAASTRO clinic 相关的临床结果

登录后查看更多信息

0 项与 MAASTRO clinic 相关的专利（医药）

登录后查看更多信息

134

项与 MAASTRO clinic 相关的文献（医药）

2024-06-01·Technical Innovations & Patient Support in Radiation Oncology

The Radiation Therapist profession through the lens of new technology: A practice development paper based on the ESTRO Radiation Therapist Workshops

Article

作者: Denney, Elizabeth ; Woodford, Katrina ; van den Bosch, Maud ; Curic, Ilija ; Thompson, Kenton ; Kearney, Maeve ; Dean, Jenna ; Leech, Michelle ; Abdalqader, Alaa ; Alexander, Sophie ; Leung, Vincent W S ; Povilaitis, Justas ; Nirgianaki, Eleftheria ; Anderson, Nigel ; Chapman, Victoria ; Mortsiefer, Martina ; Buijs, Monica ; Callens, Dylan ; Strikou, Dimitra ; Coffey, Mary ; Barbosa, Barbara ; Cox, Maya ; Leung, Vincent W.S. ; Velec, Michael

Technological advances in radiation therapy impact on the role and scope of practice of the radiation therapist. The European Society of Radiotherapy and Oncology (ESTRO) recently held two workshops on this topic and this position paper reflects the outcome of this workshop, which included radiation therapists from all global regions. Workflows, quality assurance, research, IGRT and ART as well as clinical decision making are the areas of radiation therapist practice that will be highly influenced by advancing technology in the near future. This position paper captures the opportunities that this will bring to the radiation therapist profession, to the practice of radiation therapy and ultimately to patient care.

2024-02-15·International Journal of Cancer

Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”

Letter

作者: Vega, Ana ; Aguado-Barrera, Miguel E ; Seibold, Petra ; Briers, Erik ; Webb, Adam ; Gutiérrez-Enríquez, Sara ; Chang-Claude, Jenny ; Veldeman, Liv ; Azria, David ; West, Catharine ; Taboada-Valladares, Begoña ; Talbot, Christopher ; Rosenstein, Barry ; Reyes, Victoria ; Giraldo, Alexandra ; Rattay, Tim ; Elliott, Rebecca ; De Ruysscher, Dirk ; Rosas, Juan C ; Farcy-Jacquet, Marie-Pierre ; Sperk, Elena ; Stobart, Hilary ; Ward, Tim ; Rancati, Tiziana

2023-12-01·Clinical Cancer Research

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Article

作者: McCluggage, W Glenn ; Oosting, Jan ; Ip, Philip P C ; Lutgens, Ludy ; Slot, Annerie ; Mens, Jan Willem ; Creutzberg, Carien L ; Kramer, Claire J H ; Jobsen, Jan J ; Jürgemlienk-Schulz, Ina ; Haverkort, Marie A D ; Vermij, Lisa ; Singh, Naveena ; Lax, Sigurd F ; Howitt, Brooke E ; Bosse, Tjalling ; Jamieson, Amy ; Horeweg, Nanda ; Gilks, C Blake ; Nout, Remi A ; McAlpine, Jessica N ; Carlson, Joseph

AbstractPurpose:The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort.Experimental Design:Previously diagnosed stage I p53abn EC (POLE–wild-type, mismatch repair–proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan–Meier method was used for survival analysis.Results:We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients.Conclusions:A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.

项与 MAASTRO clinic 相关的新闻（医药）

2019-02-08

·BioSpace

MAASTRO Clinic Begins Treatments with Mevion Proton System

LITTLETON, Mass.--(BUSINESS WIRE)-- The Zuid-Oost Nederland Protonen Therapie Centrum, (ZON-PTC) at the MAASTRO Clinic in Maastricht, the Netherlands has become the first center in Europe to provide proton therapy to patients utilizing a compact, single-room system. The center features the MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning and an integrated in-room cone beam CT system, the ImagingRing™* from medPhoton. This press release features multimedia. View the full release here: Team members from ZON-PTC and Mevion gather to celebrate the first patient treatment. (Photo: Business Wire) Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. HYPERSCAN Pencil Beam Scanning improves on these benefits by utilizing an adaptive multi-leaf collimator to sharpen the beam and enable a more precise and conformal dose to the tumor than ever before. “Proton therapy is an important tool in cancer treatment, and we are excited to now offer this advanced form of proton therapy to patients who need it most,” said Geert Bosmans, managing director of ZON-PTC. Mevion’s streamlined installation allowed the clinicians at ZON-PTC to begin treating patients in less than a year from cyclotron delivery. Moreover, with the industry’s smallest footprint, the proton system was directly embedded into the radiation therapy department in a narrow space between two clinical buildings. This enables ZON-PTC to share existing resources and expand the treatment options available at the MAASTRO Clinic. “This opening is part of Mevion’s mission to provide global access to this advanced cancer-fighting tool,” said Tina Yu, CEO of Mevion. “We are very proud to partner with MAASTRO Clinic to open the ZON-PTC, and we look forward to many years of collaboration and research.” Adoption of proton therapy has been expanding rapidly because of the development of compact proton therapy systems. Today, new proton therapy systems are almost exclusively compact single-room systems. Mevion was the first company to innovate this new approach to proton therapy and provides the most compact system available today. *The ImagingRing from medPhoton is 510(k) pending and has not been cleared by the US FDA for clinical use. About Mevion Medical Systems Mevion Medical Systems, Inc. is the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe and China. For more information, please visit . Follow Mevion on Twitter: Connect with Mevion on LinkedIn:

放射疗法

100 项与 MAASTRO clinic 相关的药物交易

登录后查看更多信息

100 项与 MAASTRO clinic 相关的转化医学

登录后查看更多信息